Tolerance of a Motorized Orthosis Reproducing Walking Movement vs Conventional Standing-up Devices in Child With CP (EOMEC/CP)

June 9, 2026 updated by: Lille Catholic University

Tolerance of a Motorized Orthosis Reproducing Walking Movement Versus Conventional Passive Standing-up Devices in Children With Cerebral Palsy : A Non-inferiority, Randomised, Multicenter, Controlled Trial

Cerebral palsy (CP) includes all the sensorimotor development disorders leading to balance, gait and movement disruptions. These disorders are related to lesions of the central nervous system (CNS) that occurs at birth or during the early childhood. The therapeutic management of CP is essentially based on reeducation, but may also require specific medical treatments, orthopedic devices and sometimes bone surgery. Therefore, CP children are very often placed in specialized institutions with a significant socioeconomic impact. CP children suffer from various sensorimotor impairments, which may evolve into orthopedic deformations, justifying the implementation of restrictive devices. The French High Authority of Health (HAS) estimates that 50 % of CP children have pains when using contention or verticalization devices. These pains are mainly nociceptive and are caused by the passive constraint applied on contact points. Many clinical trials evaluating the physiotherapy benefits on CP patients have led to controversial results regarding the duration of the effect of this therapeutic approach. However, the improvement is more important when neuromuscular facilitation techniques are added to the reeducation program. Human neuronal adaptation and plasticity mechanisms are now understood, with the possibility of a potential partial recovery. Non-invasive stimulation methods and neurorehabilitation techniques could participate in the CNS re-calibration. Automated assisted movements have already been used and these processes showed an increase joint range of motion, bone density and decreased spasticity.

In recent years, "exoskeleton" devices have been used on subjects with spinal cord injuries allowing motor performances improvement.

This pilot study aims evaluating CP children's tolerance to motorized orthosis reproducing walking pattern compared with conventional passive standing-up devices. For this clinical trial, the investigators compare the behavior of CP children using a motorized orthosis reproducing walking pattern (Innowalk Pro Small) to the behavior of same children placed in their usual conventional passive device. The investigators hypothesis is that the Innowalk improves joints range of motion, enhances selective motor control, decreases the medium-term spasticity and offers at least the same tolerance as conventional passive devices.

Study Overview

Status

Terminated

Conditions

Study Type

Interventional

Enrollment (Actual)

25

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Saint-Fargeau-Ponthierry, France, 77310
        • IEM Ellen Poidatz
    • Hauts-de-France
      • Béthune, Hauts-de-France, France, 62400
        • IEM Sévigné
      • Liévin, Hauts-de-France, France, 62803
        • IEM Vent de Bise
      • Villeneuve-d'Ascq, Hauts-de-France, France, 59653
        • IEM Christian Dabbadie

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

6 years to 16 years (Child)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • CP children from 6 to 16 years old, and being less than 150 cms, able to receive a 30 minutes verticalization session (standard practice) without sign of discomfort or intolerance
  • Communicating children
  • Children who had never walked

Exclusion Criteria:

  • Children presenting uncontrolled epileptic seizures
  • No social insurance affiliation
  • Refuse to participate in the study
  • Orthopaedic surgery in 6 months which precede the inclusion.
  • Injection of botulinum toxin in the 6 months which precede the inclusion.
  • Previous neurotomy

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Experimental
Group of communicating CP children receiving a 30 minutes daily session of verticalization with a motorized orthosis reproducing walking movement (PS Innowalk)
Other: Control
Group of communicating CP children receiving a 30 minutes daily session of verticalization with their conventional passive stander.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Tolerance of pain according to the scale PPP (paediatric pain profile)
Time Frame: 6 weeks
Paediatric Pain Profile (PPP) pain scale, validated for children with CP and completed by the carer (hetero questionnaire), assessed at D0, D1, W3 and W6.
6 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Lower limb muscular strength measured by the Ashworth scale
Time Frame: 6 weeks
Ashworth muscle tone scale (assessment of spasticity). This validated scale is used to test the muscular reaction to stretching.
6 weeks
Lower limb articular amplitudes measured by a goniometer
Time Frame: 6 weeks
Assessment of joint amplitudes using goniometry. This passive assessment will be carried out for the ankle, knee and hip joints.
6 weeks
Selective motor control measured by the CMS/Boyd scale
Time Frame: 6 weeks
Evaluation of selective motor control using the CMS/Boyd scale.
6 weeks
Stress evaluation measured by the change in heart rate from baseline linked to the verticalization system
Time Frame: 6 weeks
Heart rate
6 weeks
Identification and quantification (percentage) of adverse events and complications linked to the verticalization system
Time Frame: 6 weeks
Number of complications (epileptic seizures, lesions, fractures, malaise, etc.) occurring during the study, description of these, severity grade, evolution, responsibility of the equipment, etc
6 weeks
Number of days of utilization of the verticalization system until first complication or withdrawal of the study.
Time Frame: 6 weeks
Time of use of device until first complication Time in use of device until discontinuation due to complication
6 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

November 1, 2015

Primary Completion (Actual)

November 1, 2018

Study Completion (Actual)

November 18, 2018

Study Registration Dates

First Submitted

January 27, 2016

First Submitted That Met QC Criteria

January 28, 2016

First Posted (Estimated)

January 29, 2016

Study Record Updates

Last Update Posted (Actual)

June 11, 2026

Last Update Submitted That Met QC Criteria

June 9, 2026

Last Verified

June 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on CP (Cerebral Palsy)

Clinical Trials on PC Innowalk

Subscribe